STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Francis (Frank) Perier, Jr. as Chief Financial Officer (CFO). Mr. Perier previously served as the CFO of Forest Laboratories, Inc. for ten years, prior to its acquisition by Actavis in 2014. He was the Executive Vice President of Finance and during his tenure had the experience of leading the finance, human resources and legal functions.
“It is my pleasure to welcome Frank to SpringWorks. Frank’s many years of broad finance and operating experience is ideally suited to the next phase of growth for SpringWorks,” said Saqib Islam, Chief Executive Officer of SpringWorks. “We look forward to his leadership as we aim to build a leading targeted oncology company that develops and delivers life-changing medicines for patients suffering from devastating rare diseases and cancer.”
“SpringWorks is a unique company with a noble purpose,” said Mr. Perier. “I am very impressed by the accomplishments of the team since the company’s launch just two years ago and look forward to bringing my experience and skills to help the team execute on their vision.”
Prior to joining Forest, Mr. Perier was with Bristol-Myers Squibb Company for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning - Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Mr. Perier was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company.
Mr. Perier received a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Science in Accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
About SpringWorks Therapeutics
At SpringWorks, a clinical-stage biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer. Since our launch in 2017, we have worked to identify and advance promising science, beginning with our licensed clinical therapies from Pfizer Inc. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients. Nirogacestat, our gamma secretase inhibitor for the treatment of desmoid tumors is currently in a Phase 3 clinical trial, and SpringWorks expects to initiate a Phase 2b clinical trial of mirdametinib, our MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas, in the third quarter of 2019. Mirdametinib also holds promise as the backbone for combination therapies to treat metastatic solid tumors. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients. For more information, please visit www.springworkstx.com.
Follow SpringWorks Therapeutics on social media: @SpringWorksTx and LinkedIn.
